Introduction
Genital lichen sclerosus (LS) is a chronic inflammatory disease usually managed with intermittent potent topical corticosteroids.5% of women with untreated vulval LS go on to develop squamous cell carcinoma (SCC).
Current guidelines from the British Association of Dermatologists (BAD) state that patients on topical corticosteroids should be reviewed at least annually by their General Practitioner (GP) [1]. Previous work has shown that many women discharged from secondary to primary care are lost to follow-up [2].